Journal of clinical lipidology最新文献

{"title":"Omega-3 supplementation and Lp-PLA2: Attention to nonindependent comparisons in meta-analysis.","authors":"Jiyu Zhao, Jing Yan","doi":"10.1016/j.jacl.2026.04.014","DOIUrl":"https://doi.org/10.1016/j.jacl.2026.04.014","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Identification of a novel apoB variant in a family exhibiting hypocholesterolemia: Mechanistic insights\" [J Clin Lipidol (2026) S1933-2874(26)00045-0, ahead of print].","authors":"Rachid Essalmani, Alexandra Evagelidis, Anna Roubtsova, Michael Chong, Nazia Pathan, Guillaume Pare, Evgeniy V Petrochenko, Mart Reimund, Alan T Remaley, Lorraine Chalifour, Morris Schweitzer, Nabil G Seidah","doi":"10.1016/j.jacl.2026.04.001","DOIUrl":"https://doi.org/10.1016/j.jacl.2026.04.001","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147772739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 2-year randomized trial of pitavastatin calcium versus placebo to treat combined dyslipidemia in adolescents with overweight and obesity.","authors":"Brian W McCrindle, Silva Arslanian, Michele Mietus-Snyder, Elaine M Urbina, Adam L Ware, Jessica E Teng, Felicia Trachtenberg, Mark W Russell, Amy S Shah, Mark Cartoski, Julie A Brothers, Christine San Giovanni, Justin P Zachariah, Sandra Pena, William T Mahle, Amy L Peterson, Sheela N Magge, Geetha Raghuveer, Binu Sharma, Valiantsina Kazlova, Craig A Sponseller, D 'Andrea Freemon, Mario Stylianou, Sarah D de Ferranti","doi":"10.1016/j.jacl.2026.04.007","DOIUrl":"https://doi.org/10.1016/j.jacl.2026.04.007","url":null,"abstract":"<p><strong>Background: </strong>Combined dyslipidemia of overweight/obesity (CDO) is prevalent in youth and is associated with an increased risk of early cardiovascular disease.</p><p><strong>Objective: </strong>We sought to determine the impact and safety of statin therapy for CDO in adolescents.</p><p><strong>Methods: </strong>A double-blind, randomized trial was performed across 18 North American sites. Participants aged 10 to 19 years with body mass index ≥85th %ile and CDO defined as non-high-density lipoprotein cholesterol (HDL-C) ≥120 mg/dL (3.10 mmol/L) and either low HDL-C or high triglyceride:HDL-C ratio were randomized centrally to receive either pitavastatin calcium 4 mg/d or placebo for 2 years. The primary outcome was change in carotid-femoral pulse wave velocity (PWV), assessed at baseline, 6, 12, 18, and 24 months. Secondary outcomes included safety and lipid measures.</p><p><strong>Results: </strong>The intention-to-treat analysis included 59 participants (33 males) who received pitavastatin calcium and 60 who received placebo (32 males), enrolled from June 2018 to April 2021. There were no significant changes or trends for PWV in either group. Compared with placebo, at 24 months, pitavastatin was associated with significantly reduced low-density lipoprotein cholesterol (from 134 ± 23 mg/dL [3.47 ± 0.60 mmol/L] to 105 ± 25 mg/dL [2.72 ± 0.65] pitavastatin vs 130 ± 25 mg/dL [3.37 ± 0.65] to 126 ± 27 mg/dL [3.26 ± 0.70] placebo; P < .001). There was 1 serious adverse event (placebo), and no significant differences in liver enzymes, muscle toxicity, glucose homeostasis, or linear growth.</p><p><strong>Conclusion: </strong>Over 2 years, treatment with pitavastatin calcium of CDO for adolescents resulted in no changes in vascular measures. Statin therapy safely lowered atherogenic lipid particles, potentially reducing cardiovascular risk.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonstatins for LDL-C lowering: An expansion whose time has come.","authors":"Joseph J Saseen, Dave L Dixon","doi":"10.1016/j.jacl.2026.04.017","DOIUrl":"https://doi.org/10.1016/j.jacl.2026.04.017","url":null,"abstract":"<p><p>The 2026 American College of Cardiology/American Heart Association/Multisociety Dyslipidemia Guideline marks a defining moment for lipidology with the reinstatement of low-density lipoprotein cholesterol (LDL‑C) and non-high-density lipoprotein cholesterol treatment goals and a decisive endorsement of combination lipid‑lowering therapy. Although statins remain foundational, statin monotherapy often fails to achieve sufficient LDL‑C lowering, particularly in high-risk patients or patients with statin intolerance or refusal. These realities elevate nonstatin therapies from secondary considerations to core components of evidence‑based care. This commentary reviews the expanded role of currently available nonstatin agents across all guideline‑defined treatment groups. New outcomes data further strengthen the rationale for greater LDL‑C reduction in high‑risk primary prevention populations and reinforce the \"lower is better\" principle central to lipidology. Finally, we explore the rapidly evolving pipeline of next‑generation LDL‑C-lowering therapies, including long‑acting injectables and oral proprotein convertase subtilisin/kexin type 9 inhibitors, that promise to further individualize care and address longstanding barriers to adherence and goal attainment. These advances underscore a new lipid‑lowering paradigm that includes combination therapy to achieve and sustain optimal LDL‑C levels and meaningfully reduce atherosclerotic cardiovascular disease risk.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147864029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to the editor by Liu and colleagues.","authors":"Tomoaki Yamada, Yasushi Yamamoto, Ryoko Toragai, Yoshiyuki Watanabe, Toshio Kuroshima, Masako Arimoto, Marie Nakamura, Yasuki Ito, Masumi Ai","doi":"10.1016/j.jacl.2026.04.010","DOIUrl":"https://doi.org/10.1016/j.jacl.2026.04.010","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838507","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early-pregnancy remnant cholesterol as a modifiable risk factor for gestational diabetes mellitus.","authors":"Mei-Mei Hu, Shu-Yu Li, Lan-Lan Xiang, Yi-Tian Zhu, Yi-Ting Chen, Yun Liu, Ya-Jun Chen, Yu Zeng, Tian-Ying Zhong","doi":"10.1016/j.jacl.2026.04.012","DOIUrl":"https://doi.org/10.1016/j.jacl.2026.04.012","url":null,"abstract":"<p><strong>Background: </strong>Remnant cholesterol (RC) is a known contributor to cardiovascular disease, but its role in gestational diabetes mellitus (GDM) remains insufficiently characterized.</p><p><strong>Objective: </strong>To examine the association between first-trimester RC levels and GDM risk, and to quantify the mediating effects of prepregnancy body mass index (BMI) and insulin sensitivity.</p><p><strong>Methods: </strong>This prospective cohort study included 877 pregnant women in Southeastern China. RC was calculated from first-trimester fasting lipid profiles. GDM was diagnosed via a 75 g oral glucose tolerance test at 24 to 28 weeks. Binary logistic regression, restricted cubic splines, and serial mediation models were employed for analysis.</p><p><strong>Results: </strong>Among all participants, 160 (18.2%) developed GDM. After full adjustment for confounders, women in the highest quartile of first-trimester RC had a significantly higher risk of GDM (odds ratio = 2.850, 95% CI: 1.679-4.836) compared with those in the lowest quartile. A significant positive dose-response relationship was observed (P for overall < .001). Serial mediation analysis indicated that the association between RC and GDM was partially mediated through the sequential pathway of prepregnancy BMI → Matsuda index, accounting for 13.50% of the total effect. RC also showed modest predictive performance for GDM (area under the curve = 0.673) compared with conventional lipid parameters.</p><p><strong>Conclusion: </strong>Elevated first-trimester RC is independently associated with increased GDM risk. This association is partially mediated by prepregnancy BMI and subsequent insulin resistance. Measuring RC in early pregnancy may improve the identification of women at high risk for GDM.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147856532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sleep quality and small dense LDL-C: Analytic clarifications and clinical context.","authors":"Pengliang Liu, Nan Zhang, Erping Xu","doi":"10.1016/j.jacl.2026.02.025","DOIUrl":"https://doi.org/10.1016/j.jacl.2026.02.025","url":null,"abstract":"","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147772747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early administration of low molecular weight heparin in hypertriglyceridemia-induced acute pancreatitis: A propensity score-matched retrospective cohort study.","authors":"Jianhua Wan, Maobin Kuang, Shixuan Xiong, Yaoyu Zou, Wenhua He, Yin Zhu, Nonghua Lu, Liang Xia","doi":"10.1016/j.jacl.2026.03.029","DOIUrl":"https://doi.org/10.1016/j.jacl.2026.03.029","url":null,"abstract":"<p><strong>Background: </strong>The incidence of hypertriglyceridemia-induced acute pancreatitis (HTG-AP) is rising and is prone to a poor prognosis. Low molecular weight heparin (LMWH) has garnered attention in acute pancreatitis treatment due to its anti-inflammatory, microcirculation-improving effects, but evidence for its efficacy and safety specifically in HTG-AP is limited.</p><p><strong>Objective: </strong>To evaluate the impact of early LMWH administration (within 48 hours of admission) on in-hospital mortality and other clinical outcomes in patients with HTG-AP.</p><p><strong>Methods: </strong>Based on a single-center database (2005-2023), 2862 patients with HTG-AP were included (LMWH group: 960; non-LMWH group: 1902). LMWH treatment was administered within 48 hours of admission (mean duration: 7 days). The primary outcome was in-hospital mortality. Secondary outcomes included persistent organ failure and bleeding complications. Propensity score matching (PSM), inverse probability of treatment weighting (IPTW), and overlap weighting (OW) were used to adjust for baseline differences and evaluate LMWH efficacy.</p><p><strong>Results: </strong>After adjustment with PSM, IPTW, and OW, mortality was significantly lower in the LMWH group compared with the non-LMWH group (adjusted hazard ratio 0.44-0.47, all P < .05). LMWH significantly reduced the risk of persistent organ failure (P < .01) and the need for continuous renal replacement therapy (5.3% vs 8.3%, P = .01), without increasing bleeding risk (gastrointestinal bleeding: 0.3% vs 0.7%; abdominal bleeding: 1.0% vs 0.6%, all P > .05). Subgroup analysis showed more pronounced benefits in patients aged <60 years, those with diabetes, or those with Acute Physiology and Chronic Health Evaluation II ≥8.</p><p><strong>Conclusion: </strong>Early application of LMWH was associated with a significant reduction in mortality and organ failure risk in patients with HTG-AP without increasing bleeding complications. Patients with severe disease, diabetes, or high inflammatory burden may derive greater benefit, but further mechanistic studies are needed to guide patient selection.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A real-world study on the risk of acute pancreatitis and cardiovascular events among adults with severe or extreme hypertriglyceridemia.","authors":"Asia Sikora Kessler, Kirti Batra, Qiana Amos, Seth J Baum, Daniel E Soffer, Montserrat Vera-Llonch","doi":"10.1016/j.jacl.2026.04.002","DOIUrl":"https://doi.org/10.1016/j.jacl.2026.04.002","url":null,"abstract":"<p><strong>Background: </strong>Severe hypertriglyceridemia (sHTG) has a causal role in acute pancreatitis (AP), whereas the relationship between triglyceride (TG) levels and risk of cardiovascular (CV) events is less well-known.</p><p><strong>Objective: </strong>To assess the incidence, risk, and odds of AP and CV events among US adults with sHTG and hypertriglyceridemia (HTG) compared to those with normal TG levels.</p><p><strong>Methods: </strong>The Optum Research Database identified 4 cohorts of adults with a TG test between January 1, 2017, and March 31, 2021. sHTG (500 ≤ TG <880 mg/dL) and extreme HTG (eHTG; TG ≥880 mg/dL) were identified first, followed by random identification of normal TG (35 ≤ TG <150 mg/dL) and HTG (150 ≤ TG <500 mg/dL) cohorts. Primary outcomes included incidence, adjusted risk, and adjusted odds of AP and CV events.</p><p><strong>Results: </strong>A total of 134,116 patients were included: 46,676 (34.8%) with normal TG, 54,090 (40.3%) with HTG, 28,556 (21.3%) with sHTG, and 4994 (3.7%) with eHTG. Incidents of both outcomes were significantly higher for HTG, sHTG, and eHTG, compared with normal TG (P < .001). Adjusted hazard ratios (HRs) of AP were 1.491, 2.586, and 4.695 for HTG, sHTG, and eHTG, respectively (all P < .001). Adjusted HRs of CV events were 1.163 and 1.206 for sHTG and eHTG, respectively (both P < .001).</p><p><strong>Conclusion: </strong>In this cohort study, patients with sHTG and eHTG had significantly higher incidence of AP and CV events, compared with those with normal TG. The adjusted risk of AP and CV events increased stepwise with TG level; the association was stronger for AP.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147838527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline leptin and longitudinal LDL-C changes in relation to sleep-disordered breathing: The Toon Health Study.","authors":"Sakurako Tanno, Ai Ikeda, Taro Kishida, Koutatsu Maruyama, Isao Saito, Takeshi Tanigawa","doi":"10.1016/j.jacl.2026.04.003","DOIUrl":"https://doi.org/10.1016/j.jacl.2026.04.003","url":null,"abstract":"<p><strong>Background: </strong>Existing evidence regarding the effect of leptin on low-density lipoprotein cholesterol (LDL-C) is inconsistent. One possible explanation for this inconsistency is sleep-disordered breathing (SDB), a common condition associated with both leptin and dyslipidemia.</p><p><strong>Objective: </strong>This study aimed to clarify the role of leptin in the regulation of LDL-C in humans and to examine whether SDB modifies this association.</p><p><strong>Methods: </strong>We analyzed data from the Toon Health Study. Among those who completed baseline examinations, leptin and LDL-C measurements were available for 1113 participants. Follow-up examinations were conducted 5 years later. SDB was assessed using overnight pulse oximetry. Longitudinal changes in LDL-C were evaluated using linear mixed-effects models. Serum leptin levels were analyzed in sex-specific quartiles; for stratified analyses, high leptin was defined as above the sex-specific 75th percentile.</p><p><strong>Results: </strong>Over the 5-year follow-up period, upper-quartile baseline leptin levels were associated with a pronounced decline in LDL-C compared with the lowest quartile. Comparison of the high and low leptin groups revealed that this association was evident only among participants without SDB (n = 149 and 570, respectively). When a stricter cutoff of oxygen desaturation index (<2) was applied, the association remained significant (n = 79 and 347, respectively). Moreover, the 3-way interaction term (leptin × time × SDB status) reached statistical significance.</p><p><strong>Conclusion: </strong>Higher baseline leptin levels were associated with a statistically significant decline in LDL-C over 5 years, particularly among individuals without SDB. These results suggest that SDB modifies the longitudinal association between leptin and LDL-C.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147815799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}